Abstract:High-dose radiation activates caspases in tumor cells to produce abundant DNA fragments for DNA sensing in antigen-presenting cells, but the intrinsic DNA sensing in tumor cells after radiation is rather limited. Here we demonstrate that irradiated tumor cells hijack caspase 9 signaling to suppress intrinsic DNA sensing. Instead of apoptotic genomic DNA, tumor-derived mitochondrial DNA triggers intrinsic DNA sensing. Specifically, loss of mitochondrial DNA sensing in Casp9-/- tumors abolishes the enhanced therapeutic effect of radiation. We demonstrated that combining emricasan, a pan-caspase inhibitor, with radiation generates synergistic therapeutic effects. Moreover, loss of CASP9 signaling in tumor cells led to adaptive resistance by upregulating programmed death-ligand 1 (PD-L1) and resulted in tumor relapse. Additional anti-PD-L1 blockade can further overcome this acquired immune resistance. Therefore, combining radiation with a caspase inhibitor and anti-PD-L1 can effectively control tumors by sequentially blocking both intrinsic and extrinsic inhibitory signaling.

Author Correction: Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling

Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling (vol 21, pg 546, 2020)

Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling

Author Correction: A Next-Generation Tumor-Targeting IL-2 Preferentially Promotes Tumor-Infiltrating CD8+ T-cell Response and Effective Tumor Control

Author Correction: PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis

Author Correction: Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

Corrigendum: Tumor-Associated Macrophages in Tumor Immunity

Author Correction: Suppression of Glioblastoma by a Drug Cocktail Reprogramming Tumor Cells into Neuronal Like Cells

Author Correction: Caspase-11 Signaling Enhances Graft-Versus-host Disease

Correction To: Long Non-Coding RNA HOTTIP Enhances IL-6 Expression to Potentiate Immune Escape of Ovarian Cancer Cells by Upregulating the Expression of PD-L1 in Neutrophils.

Correction: the Lipogenic LXR-SREBF1 Signaling Pathway Controls Cancer Cell DNA Repair and Apoptosis and is a Vulnerable Point of Malignant Tumors for Cancer Therapy.

Correction to: FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway

Author Correction: A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts

Correction: Infiltrating Mast Cells Increase Prostate Cancer Chemotherapy and Radiotherapy Resistances Via Modulation of P38/p53/p21 and ATM Signals.

Author Correction: Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells

Publisher Correction: Landscape of B cell immunity and related immune evasion in human cancers

Author Correction: Cyclin D–CDK4 Kinase Destabilizes PD-L1 Via Cullin 3–SPOP to Control Cancer Immune Surveillance

Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

Correction: CSN6–TRIM21 axis instigates cancer stemness during tumorigenesis

Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Corrigendum: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway